Could a new MRI technique spot hidden breast lesions better than ultrasound?
NCT ID NCT07679308
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study looks at whether a detailed MRI scan (called multiparametric DCE-MRI) can improve the detection of breast lesions that don't form a clear lump on ultrasound. Researchers will compare the MRI results with ultrasound findings in 60 women to see if the MRI provides a more accurate diagnosis. The goal is to help doctors make better decisions about whether these lesions are harmless or need further attention.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- multiparametric DCE-MRI
- What this could lead to
- If successful, this could make breast cancer detection more accurate for hard-to-see lesions, reducing missed diagnoses.
- What could go wrong
- This is a small, early-stage study with only 60 participants, so results may not apply to everyone. MRI is also expensive and not widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Female patients of any age group presented with non mass lesions on either US or mammography
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Female patients of any age presenting with non-mass breast lesions detected on MRI or conventional imaging. * Patients who have both MRI and targeted Ultrasound examinations. Exclusion Criteria: * • Patients presenting with typical distinct "mass" lesions (3D space-occupying lesions) without any non-mass components. * Patients with absolute contraindications to MRI (e.g., cardiac pacemakers, severe claustrophobia, non-compatible metallic implants). * Patients with contraindications to intravenous Gadolinium contrast media (e.g., severe renal impairment/failure, pregnancy, known history of severe allergic reaction to gadolinium).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non mass breast lesions are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.